CARBOGEN AMCIS Vionnaz Facility Completes First FDA Pre-Approval Inspection Without Form 483

CARBOGEN AMCIS has announced the successful completion of its first U.S. Food and Drug Administration (FDA) Pre-Approval Inspection (PAI) at its Vionnaz facility in Switzerland. The inspection, conducted from September 7 to September 11, 2026, concluded without the issuance of a Form 483.

The FDA inspection was carried out as part of the regulatory review of a pharmaceutical product manufactured at the Vionnaz site. During the inspection, regulators examined several areas associated with the product and its manufacturing process, covering both operational and quality-related requirements.

The assessment included manufacturing and batch documentation, process validation and equipment qualification. FDA inspectors also reviewed analytical method validation and cleaning validation procedures. Other areas examined included supplier qualification, change-control systems, deviation management, corrective and preventive actions (CAPA), and employee training.

CARBOGEN AMCIS said the outcome represents a significant milestone for its Vionnaz operation and reflects the site’s focus on maintaining quality and regulatory compliance. The company highlighted the facility’s role in the development and small-scale manufacture of highly potent active pharmaceutical ingredients (APIs).

The Vionnaz site specialises in highly potent compounds, including warheads and linkers used in antibody-drug conjugate development. It has dedicated facilities for process development, production and quality-control activities.

A Form 483 is issued by the FDA when investigators identify conditions or practices that may constitute violations of regulatory requirements. The absence of a Form 483 at the conclusion of this inspection means that no such observations were issued during the inspection.

CARBOGEN AMCIS said its teams had worked extensively to prepare for the inspection and would continue to maintain the quality systems and compliance standards expected for pharmaceutical manufacturing operations.

28-09-2026